Search
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalCabergoline possesses potent agonist activity on dopamine D2 receptors. … Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome.
Synonyms: (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamideLatamoxef
go.drugbank.com/drugs/DB04570ApprovedLatamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigationalzone lymphoma in selected patients. … [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal
Sulfamethoxazole
go.drugbank.com/drugs/DB01015ApprovedInvestigationalin the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. … [L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps
Mixtures: COTRIM E RATIO 480MG/5ML, EUSAPRIM E SUSPENS F ERWSynonyms: 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamideVibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalOn December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … [L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency,
Technetium Tc-99m nofetumomab merpentan
go.drugbank.com/drugs/DB09336ApprovedWithdrawnIt was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082] … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992.
Tocainide
go.drugbank.com/drugs/DB01056ApprovedWithdrawnAn antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
Synonyms: 2-amino-N-(2,6-dimethylphenyl)propanamide, 2-Amino-N-(2,6-dimethylphenyl)propionamidFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[A190492] Later that year in December, the drug was also approved by the European Medicine Agency.[A190492] In June 2012, fidaxomicin was also granted approval by Health Canada. … [A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug.
Hydrocortamate
go.drugbank.com/drugs/DB00769ApprovedGlucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic
Tirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigationalTirbanibulin exhibits antitumour effects in vitro and in vivo [A225791] and has been investigated for its antitumor efficacy in the management of various cancers, such as prostate cancer and breast cancer … [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri.